These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 32427375)
1. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer. Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375 [TBL] [Abstract][Full Text] [Related]
2. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine. Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219 [TBL] [Abstract][Full Text] [Related]
3. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
4. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078 [TBL] [Abstract][Full Text] [Related]
5. Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer. Mo L; Chen Q; Zhang X; Shi X; Wei L; Zheng D; Li H; Gao J; Li J; Hu Z Vaccine; 2017 Oct; 35(43):5932-5938. PubMed ID: 28923424 [TBL] [Abstract][Full Text] [Related]
6. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470 [TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer. Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844 [TBL] [Abstract][Full Text] [Related]
9. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Hannan R; Zhang H; Wallecha A; Singh R; Liu L; Cohen P; Alfieri A; Rothman J; Guha C Cancer Immunol Immunother; 2012 Dec; 61(12):2227-38. PubMed ID: 22644735 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of Anti-Leukemia Immunity by Leukemia-Derived Exosomes Via Downregulation of TGF-β1 Expression. Huang F; Wan J; Hu W; Hao S Cell Physiol Biochem; 2017; 44(1):240-254. PubMed ID: 29130994 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. Winter H; Hu HM; McClain K; Urba WJ; Fox BA J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488 [TBL] [Abstract][Full Text] [Related]
16. HCA587 Protein Vaccine Induces Specific Antitumor Immunity Mediated by CD4 Yang W; Zhang W; Wang X; Tan L; Li H; Wu J; Wu Q; Sun W; Chen J; Yin Y Anticancer Agents Med Chem; 2021; 21(6):738-746. PubMed ID: 32723258 [TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway. Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548 [TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245 [TBL] [Abstract][Full Text] [Related]
19. Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. Xiu F; Cai Z; Yang Y; Wang X; Wang J; Cao X J Mol Med (Berl); 2007 May; 85(5):511-21. PubMed ID: 17219095 [TBL] [Abstract][Full Text] [Related]
20. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response. Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]